Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Capricor Therapeutics
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
August 24, 2026
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 20, 2026
Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
August 19, 2026
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
August 19, 2026
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
August 18, 2026
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
August 18, 2026
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
May 5, 2026
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
April 22, 2026
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 13, 2026
1
2
Next Page
→